Johnson & Johnson (JNJ)
| Market Cap | 653.97B +35.7% |
| Revenue (ttm) | 99.34B +7.8% |
| Net Income | 16.10B -35.9% |
| EPS | 6.58 -36.4% |
| Shares Out | 2.41B |
| PE Ratio | 41.26 |
| Forward PE | 24.39 |
| Dividend | $5.36 (1.97%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | 1,508,019 |
| Open | 270.36 |
| Previous Close | 267.14 |
| Day's Range | 269.47 - 272.15 |
| 52-Week Range | 199.38 - 290.25 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 279.85 (+3.02%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $279.85, which is an increase of 3.02% from the latest price.
News
Johnson & Johnson reports results from Phase 4 STAR study of TREMFYA
Johnson & Johnson announced late-breaking results from the Phase 4 STAR study of TREMFYA in biologic-naive adults with active psoriatic arthritis and axial involvement. TREMFYA met primary and major s...
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 stud...
Johnson & Johnson price target raised to $300 from $285 at JPMorgan
JPMorgan raised the firm’s price target on Johnson & Johnson to $300 from $285 and keeps a Neutral rating on the shares as part of an analyst day preview. The…
Johnson & Johnson announces first commercial installation of OTTAVA system
Johnson & Johnson announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA Robotic Surgical System, representing a major milestone in the...
Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA™ Robotic Surgical ...
Johnson & Johnson submits sNDA to FDA for approval of caplyta in bipolar mania
Johnson & Johnson announced the submission of a supplemental New Drug Application to the U.S. FDA seeking the approval of caplyta for the treatment of manic or mixed episodes associated…
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication
Two positive Phase 3 studies showed CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 As the first and only FDA-approved treatmen...
Johnson & Johnson price target raised to $292 from $275 at BofA
BofA raised the firm’s price target on Johnson & Johnson to $292 from $275 and keeps a Neutral rating on the shares. The company enters its December 8th Enterprise Business…
Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson
DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mes...
Blackstone Life Sciences announces $750M R&D funding agreement
Blackstone (BX) announced that funds managed by Blackstone Life Sciences will provide $750M in development funding to Johnson & Johnson (JNJ) to support the Phase 3 clinical development of OLN324,…
Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
Johnson & Johnson to acquire Ollin Biosciences for $2.2B upfront
Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfro...
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmac...
M&A News: Johnson & Johnson Has $3.4B Eye Biotech Ollin Biosciences in Its Sights
Shares in U.S. medical giant Johnson & Johnson ($JNJ) were higher in pre-market trading today on reports that it has set its sights on buying eye disease biotech Ollin Biosciences…
The Big 3: JNJ, LLY, AAPL
Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks i...
Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for...
Johnson & Johnson’s Caplyta shows improvement in Phase 2 bipolar mania study
Johnson & Johnson announced that Study 452, the second pivotal Phase 3 study evaluating Caplyta – lumateperone – for the treatment of manic episodes with or without mixed features in…
J&J eyes US nod for Caplyta in bipolar mania after second trial win
Johnson & Johnson said on Tuesday its drug Caplyta eased manic symptoms better than placebo in a second late-stage study of patients with bipolar I disorder, paving the way for a planned US regulato...
Dean Omar Branham Shirley Secures $3,325,000 Verdict Against Johnson & Johnson in Mesothelioma Case
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a $3,325,000 jury verdict against Johnson & Johnson on behalf of the family of Winifred “Miss...
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies Two positive Phase 3 stu...
Johnson & Johnson announces Phase 3 study of ICOTYDE met primary endpoint
Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE in biologic-naive adults with active psoriatic arthritis. ICOTYDE is the first and only targeted oral peptide th...
Johnson & Johnson announces new Phase 2 nipocalimab study data
Johnson & Johnson announced new patient experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sj gren’s disease, SjD. The results show that mouth dryness is the symptom…
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against c...
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights com...
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ...